BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme — Update
By Denny Jacob
BioMarin Pharmaceutical received a subpoena from the U.S. Justice Department for certain documents regarding sponsored testing programs related to vimizim and naglazyme.
The biotechnology company said it has produced the requested documents in response to the subpoena and is cooperating fully, according to a regulatory filing. It added that it is unable to make any assurance regarding the outcome of the investigation by the DOJ and the potential effect such an investigation would have on aspects of the company.
The DOJ declined to comment.
Vimizim is a treatment of MPS IVA, a lysosomal storage disorder. Naglazyme is a treatment for patients with MPS VI, a life-threatening genetic disease.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 26, 2024 15:55 ET (20:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now